Drug Trial Radar · NCT00842816
Preliminary Efficacy and Safety Study of ST101 Plus Aricept in Alzheimer's Disease
Last checked: Nov 19, 2026Latest source record: Jun 7, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
210
Actual
Start
Feb 2009
Primary completion
May 2011
Study completion May 2011
Sponsor
- Lead sponsor
- Sonexa Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 12, 2009
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will investigate the ability of ST101 to improve memory in people with Alzheimer's disease who currently receive 10 mg Aricept® (donepezil) per day. This study also will examine the safety and tolerability of the drug. This study is evaluating 3 different dose levels of ST101 and placebo. Patients will have a 1 in 4 chance of getting placebo. All eligible subjects will be provided with bottles of 10 mg Aricept (donepezil) during the study drug administration part of the study.
Conditions
- Alzheimer's Disease
Interventions
ST101Drug
10 mg; administered once/day
ST101Drug
60 mg; administered once/day
ST101Drug
120 mg; administered once/day
PlaceboDrug
placebo tablets to match ST101 tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Alzheimer's Disease Assessment Scale, cognitive subscale (ADAS-cog)Time frame: Baseline, 4 weeks, 8 weeks, 12 weeks
Locations
30 sites in 2 countries. Site status is shown where the registry gives one.
Site not named
Tucson, Arizona
Site not named
Costa Mesa, California
Site not named
Redlands, California
Site not named
San Diego, California
Site not named
Walnut Creek, California
Site not named
Hamden, Connecticut
Site not named
Brooksville, Florida
Site not named
Deerfield Beach, Florida
Site not named
Delray Beach, Florida
Site not named
Orlando, Florida
Site not named
St. Petersburg, Florida
Site not named
West Palm Beach, Florida
Site not named
Decatur, Georgia
Site not named
Indianapolis, Indiana
Site not named
Shreveport, Louisiana
Site not named
Summit, New Jersey
Site not named
Toms River, New Jersey
Site not named
Durham, North Carolina
Site not named
Columbus, Ohio
Site not named
Toledo, Ohio
Site not named
Jenkinton, Pennsylvania
Site not named
Norristown, Pennsylvania
Site not named
East Providence, Rhode Island
Site not named
Houston, Texas
Site not named
Wichita Falls, Texas
Site not named
Bennington, Vermont
Site not named
Kirkland, Washington
Site not named
Peterborough, Ontario, Canada
Site not named
Toronto, Ontario, Canada
Site not named
Montreal, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.